Edwards Lifesciences (NYSE:EW) VP Sells $950,632.20 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of the stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $83.83, for a total value of $950,632.20. Following the transaction, the vice president directly owned 50,356 shares in the company, valued at approximately $4,221,343.48. This represents a 18.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Edwards Lifesciences Price Performance

EW stock opened at $83.06 on Friday. The stock has a market capitalization of $48.20 billion, a price-to-earnings ratio of 35.80, a price-to-earnings-growth ratio of 3.79 and a beta of 0.97. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The stock’s fifty day simple moving average is $81.62 and its 200-day simple moving average is $79.01.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on EW. Citigroup reaffirmed a “buy” rating and set a $101.00 price target (up previously from $96.00) on shares of Edwards Lifesciences in a research report on Thursday. Truist Financial set a $92.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Royal Bank Of Canada increased their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Finally, Jefferies Financial Group set a $98.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.30.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently modified their holdings of the stock. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. Quantbot Technologies LP purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the first quarter worth $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences during the second quarter worth $28,000. Finally, True Wealth Design LLC boosted its stake in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.